Product Description
Pentamidine is used to try to prevent Pneumocystis carinii pneumonia (PCP), a very serious type of pneumonia. This type of pneumonia occurs commonly in patients whose immune systems are not working normally, such as patients with acquired immune deficiency syndrome (AIDS). (Sourced from: https://www.mayoclinic.org/drugs-supplements/pentamidine-inhalation-route/side-effects/drg-20065369?p=1)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intramuscular,Intravenous,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Belgium | Brazil | Canada | Chile | Colombia | Czech | France | Germany | Greece | Hong Kong | Ireland | Italy | Korea | Luxembourg | Malaysia | Malta | Netherlands | New Zealand | Peru | Portugal | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|